Accepterade Forskningsprojekt med RiksSvikts databas

  1. An integrative study using Swedish registries (SWEDCON,GUCH), RiksSvikt) for identification of outcomes and predictors of outcomes in adult patients with congenital heart disease. Edith Nagy/Lars Lund. Juni 2016. Stockholm
  2. Diagnostik och behandling av hjärtsvikt i primärvården. Björn Eriksson/Magnus Edner. 2016. Stockholm.
  3. Smoking, pulmonary disease and outcomes in HFrEF, HFmrEF and HFpEF. Marat Fudim. Juli 2017. Duke University USA/Stockholm
  4. Incidence, timing and characteristics of heart failure following chemotherapy for lymphoma. Sara Harrysson/Karin Ekström Smedby. Oktober 2017. Stockholm
  5. Age, gender and socioeconomic status as risk factors for non-adherence to heart failure medication; a register-based cohort study. Anna Ohlsson/Bertil Lindahl. Maj 2018. Uppsala.
  6. Sambanden mellan Diabetes typ 1 och typ 2 och HFrEF, HFmrEF och HFpEF samt deras prognostiska betydelse. Annika Rosengren/Maria Schaufelberger. Juni 2018. Göteborg
  7. Relevance and significance of left ventricular ejection fraction in heart failure: Phenotype derivation from the US PINNACLE registry linked to Medicare data and validation from the Swedish Heart Failure Registry linked to the Swedish National Patient and population registries. Hanna K Gaggin/James Januzzi. September 2018. Boston USA.
  8. From electronic health record to ejection fraction based heart failure phenotype: Development and validation of HER based algorithms for identifying HF subphenotypes (HFrEF/HFpEF). Alicia Uijl/Gianluigi Savarese. Oktober 2018. Utrecht/Stockholm
  9. Stroke prediction in chronic heart failure without atrial fibrillation – comparing different registries. Alicia Uijl/Gianluigi Savarese. Oktober 2018. Utrect/Stockholm
  10. Förlopp och sjuklighet vid kronisk andningsstörning – en registerbaserad populationsstudie. Magnus Ekström/Josefin Sundh. Oktober 2018. Karlskrona/Örebro
  11. Incidence of cancer in patients with heart failure: long term follow-up. Entela Bollano/Elmir Omerovic. November 2018. Göteborg
  12. Interaction between heart failure treatment dosage and blood pressure for clinical outcome. Nicolas Girerd/Lars Lund. December 2018. Nancy/Stockholm
  13. Role of cardiovascular and non-cardiovascular comorbidities in heart failure. Camilla Settergren/Gianluigi Savarese. Januari 2019. Stockholm
  14. The SW-EQ project: Analysis of EQ-5D profile data and EQ VAS scores across patient groups in the Swedish National Quality registers and use in developing alternative ways of summarizing EQ-5D data. Emma Naucler. Februari 2019. Göteborg
  15. Optimering av träning för kvinnor med bröstcancer – en randomiserad kontrollerad studie (OptiTrain). Yvonne Wengström. Mars 2019. Stockholm
  16. Bröstcancer och hjärtsvikt: Prevalens och behandling. En registerstudie över patienter med hjärtsvikts- och bröstcancerdiagnos. Laila Hubbert/Elham Hedayati. Maj 2019. Norrköping/Stockholm
  17. Jämförelse av patienter I SPIRRIT med patienter registrerade i RiksSvikt med avseende på riskmarkörer och utfall. Lars Lund. August 2019. Stockholm
  18. Predictors of NYHA class and their impact on outcome in heart failure. Data from the Swedish Heart Failure Registry. Benedikt Schrage/Gianluigi Savarese. September 2019.Hamburg/ Stockholm
  19. Metabola rubbningar och inflammation i relation till kronisk sjukdom, främst hjärt-kärl sjukdom. Njursjukdom, cancer, demenssjukdom, autoimmuna sjukdomar och psykisk ohälsa – epidemiologiska studier baserade på AMORIS-populationen. Niklas Hammar/Maria Feychting. December 2019. Stockholm
  20. Ärftlighet, familjefaktorer, boendemiljö och cancer; 1958-2018. Kristina Sundkvist/Henrik Ohlsson. Mars 2020. Lund
  21. Överlevnad efter hjärttransplantation – en nationell observationsstudie. Dennis Medved/Johan Nilsson. Mars 2020. Lund
  22. Interaktion mellan Covid-19 och kardiovaskulär sjukdom: epidemiologi, prognos och terapeutiska implikationer. Lars Lund/Gianluigi Savarese. Mars 2020. Stockholm
  23. Demografi och andra karakteristika, komorbiditet och riskfaktorer för Covid-19 insjuknande och prognos. Fredrik Nyberg. Juni 2020. Göteborg..
  24. Stockholm Creatinine Measurements (SCREAM) project. Jean-Jesus Carrero/Lars Lund. Augusti 2020. Stockholm
  25. Studier av orsaker, sjuklighet och behandlingsutfall vid sarkoidos. Marios Rossides/Johan Askling. Juni 2020. Stockhom
  26. Dödlighet på kort och medellång sikt efter åtgärd för brustet och/eller icke-brustet kroppspulsåderbråck i buken: 1. För olika operationstekniker, 2. För vitala respektive bräckliga patienter samt 3. För sjukhus med liten respektive stor verksamhetsvolym. Fredrik Lundgren/Thomas Troäng. Juli 2020. Kalmar/Karlskrona
  27. Personalized lifetime prediction of survival and treatment effects in patients with chronic heart failure and reduced ejection fraction. The LIFE-HF model. Pascal Burger/Gianluigi Savarese. Juli 2020. Stockholm
  28. Association of body mass index with mortality/morbidity in heart failure across ejection fraction phenotypes. Data from the Swedish Heart Failure Registry. Daniele Rodolico/ Gianluigi Savarese. April 2021. Stockholm
  29. Antiplatelet agents in Heart Failure, any prognostic role? Astrid Karlsson/Gianluigi Savarese. April 2021. Stockholm Stockholm
  30. Impact of adherence to guideline directed medical therapy on risk of mortality in patients with heart failure across ejection fraction spectrum in real world. Xiaojing Chen/ Michael Fu. Maj 2021. Chengdu – Sichuan/ Göteborg
  31. Causal association between body mass index and left ventricular mass index (LVMI) independent of blood pressure; Heart Failure implications Philip Sarajilic/Magnus Bäck. Juni 2021. Stockholm
  32. Timing and modalities of initiation/Up-titration of ARNI in patients hospitalized for HF vs outpatients with reduced ejection fraction heart failure: Real-world data from the Swedish Heart Faiure Registry. Chiara Cappelletto/Gianluigi Savarese. August 2021.
  33. Förekomst och betydelse av anemi för hjärtsviktpatienter som omhändertas inom primärvården. Anna Ugarph-Morawski/Magnus Edner. Augusti 2021. Stockholm
  34. Clustering in heart failure with reduced ejection fraction. Alicia Uijl/Lars Lund. September 2021. Stockholm
  35. Cancer in heart failure across the ejection fraction spectrum: epidemiology and association of cancer with cardiovascular treatments: Data from the Swedish Heart Failure Registry. Chiara Cappelletto/Entela Bollano. September 2021. Stockholm/Göteborg
  36. Karakterisering av hjärtsvikt; en analys av patienters fenotyper, etiologiska och prognostiska faktorer, mortalitet och morbiditet, och behandling. Gianluigi Savarese/Lars Lund. Oktober 2021. Stockholm
  37. Cardiac resynchronization therapy practice in heart failure vs electrophysiology settings/clinics in Europe. Paolo Gatti/Lars Lund. Oktober 2021. Stockholm
  38. Pharmacological treatment patterns and outcomes in patients with heart failure with and without type 2 diabetes across the ejection fraction spectrum. Francesca Musella/ Guila Ferrannini/Gianluigi Savarese. November 2021. Stockholm
  39. Phenomapping for identification of subgroups in heart failure with mildly reduced ejection fraction using data from the CHECK-HF and Swede-HF registry. Claartje Meijs/Alicia Uijl. November 2021. Utrect/Stockholm
  40. Pharmacological treatment patterns and outcomes in patients with heart failure with and without type 2 Diabetes across the ejection fraction spectrum. Francesca Musella/Gianluigi Savarese. November 2021. Stockholm
  41. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline recommended tratments – an analysis from the Swedish Heart Failure Registry. Benedict Schrage/Gianluigi Savarese. Januari 2022. Hamburg/Stockholm
  42. Change in health-related quality of life over 1 year and outcomes in patients with heart failure related to age, sex and HF subtype: Data from the Swedish Heart Failure Registry. Claire Lawson/Anna Strömberg. Januari 2022. Leicester/Linköping
  43. Värdet av hälsa och införande av nya läkemedel. Naimi Johansson. Januari 2022. Örebro
  44. Diuretic therapy as a prognostic enrichment factor for clinical trials in patients with heart failure across the ejection fraction spectrum. Marat Fudim/Lars Lund. Januari 2022. Duke University/Stockholm
  45. se – The Swedish Cohort Consortium – Cycle 2. Christian Bruzelius/Johan Sundström. Februari 2022. Uppsala
  46. world eligibility of vericiguat according to trial, guidelines and labeling eligibility criteria. Data from the Swedish Heart Failure Registry. Ngoc V. Nguyen/Gianluigi Savarese. Februari 2022. Stockholm
  47. Treatment and prognostic predictors in new-onset vs long standing heart failure. Aniza Shahim/Camilla Hage. Mars 2022. Stockholm
  48. Valvular heart diseases and heart failure – prevalence, predisposing factors, temporal trends and prognostic impact of developing Valvular heart disease after heart failure and vice versa. Bahira Shahim/Lars Lund. April 2022. Stockholm
  49. Use of SGLT2i in heart failure patients across the ejection fraction spectrum. Peter Moritz Becher/Gianluigi Savarese. April 2022. Hamburg/Stockholm
  50. Hjärtinfarkt och stroke – insjuknande, dödlighet mellan 2002-2015. Lena Björck. April 2022. Göteborg
  51. Risk factors in cardiac arrest in patients with heart failure. Meena Thuccani/Peter Lundgren. Göteborg
  52. Dödlighet och dess orsak och påverkande faktorer hos patienter med hjärtsvikt. Antros Louca/Michael Fu. Juni 2022. Göteborg
  53. Registerstudie av komplikationer efter cancer hos barn, ungdomar och unga vuxna i Sverige. Laila Hubbert/Elham Hedayati/Joakim Alfredsson/ Bertil Ekman/Margaretha Stenmarker. Juni 2022. Linköping/Stockholm/Jönköping. Juni 2022.
  54. Association between use of RASi/ARNI and betablockers with mortality/morbidity in real world heart failure patients with HFmrEF. Data from the Swedish Heart Failure Registry. Davide Stolfo/Gianluigi Savarese. August 2022. Trieste/Stockholm
  55. SGLT2i:s are associated with reduced risk of mortality and re-admission in heart failure patients. Data from the Swedish Heart Failure Registry. Patric Karlström/Michael Fu. Oktober 2022. Jönköping/Göteborg
  56. The prognostic impact of sarcoidosis in patients with heart failure. Entela Bollano/Michael Fu. Oktober 2022. Göteborg
  57. Prior myocarditis in patients with heart failure . Does it matter. Entela Bollano/Michael Fu. Göteborg.
  58. Characterizing heart failure with supranormal ejection fraction. Laura Landucci/Gianluigi Savarese. Oktober 2022. Stockholm
  59. Phenotyping patients with heart failure for N-terminal pro-B-type natriuretic peptide concentrations and testing: Data from the Swedish Heart failure Registry. Giulia Ferrannini/Gianluigi Savarese. Stockholm
  60. Menopausal hormonbehandling i relation till risk för kroniska sjukdomar och förtida död. Karin Leander Karolinska Institutet, Stockholm. Juni 2023.
  61. Assessment of drug combinations within guideline-directed medical therapy: data from the Swedish Heart Failure Registry. Giulia Ferrannini /Gianluigi Savarese. Stockholm Augusti 2023
  62. Modern heart failure treatment are associated with reduced risk of mortality compared to conventional treatment: Real-life data from the Swedish Heart Failure registry 2013-2020. Michael Fu/Patric Karlström. Augusti 2023.
  63. Previous Heart Failure Related Hospital Admissions as an Enrichment Factor for Clinical Trials in Patients with Heart Failure Across the Ejection Fraction Spectrum. Barna Szabó-Söderberg, Lars H Lund, Lina Benson, Gianluigi Savarese, Camilla Hage. September 2023.
  64. The role of cardiac resynchronization therapy for further optimization of guideline directed medical therapy in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry. Daniela Tomasoni, Lina Benson, Lars H Lund, Gianluigi Savarese. October 2023.
  65. The diuretic effect across weight classes in heart failure hospitalization – an explorative study in a real-world population from SwedeHF. Mikael Erhardsson, Ulrika Ljung Faxén, Lars H Lund, Lina Benson, Gianluigi Savarese, Camilla Hage. October 2023. 
  66. Cause-specific underlying and immediate mode of death, included suicide risk, in Heart Failure Across the Ejection Fraction Spectrum. Camilla Settergren, Bahira Shahim, Lars Lund, Lina Benson, Tonje Thorvaldsen, Angiza Shahim. November 2023.
  67. Prognosis  and  effect of glucagon-like peptide 1 (GLP-1) agonist in patients with HFpEF and obesity: data from the Swedish Heart Failure registry 2013-2020. Patric Karlström, Michael Fu, Aldina Pivodic. November 2023.
  68. Discontinuation and restart of mineralcorticoid receptor antagonists (MRA) in new users with heart failure with reduced ejection fraction (HFrEF). Laura Landucci, Lina Benson, Ulrika Ljung Faxén, Ulf Dahlström, Gianluigi Savarese, Juan-Jesus Carrero, Lars H Lund. November 2023.
Vi använder cookies
Cookies gör att denna webbplats fungerar korrekt. Genom att fortsätta använda webbplatsen godkänner du att vi använder cookies.
OK
Vår policy om cookies och personuppgifter